Annual USC Update in GI and Liver Diseases: Controversies and Guidelines in 2025

Friday, September 12, 2025, 3:00 PM - Saturday, September 13, 2025, 3:45 PM, Westin Pasadena, Pasadena, CA

AMA PRA Category 1 Credits™ (9.25 hours), Non-Physician Attendance (9.25 hours)

Recent breakthroughs in diagnosing and treating gastrointestinal and liver diseases are reshaping patient care. Innovative therapies are transforming the management of IBD, MASLD, Met-ALD, cholestatic liver diseases, and viral hepatitis B/C, while advanced endoscopic and imaging techniques are redefining our approach to pancreaticobiliary diseases, motility disorders, and early luminal neoplasia. Despite these advances, significant knowledge gaps persist.The upcoming conference aims to update community standards of practice by addressing topics such as obesity management, metabolic liver diseases, revised transplant policies, the challenges of alcoholic hepatitis, emerging transplant strategies for cholangiocarcinoma, metastatic colon cancer, and various luminal, upper GI, lower GI, and pancreatic disorders. This event will highlight the latest developments in gastroenterology and hepatology to enhance patient care.

1. Identify advances in third-space endoscopy and complicated biliary cases.
2. Explain the role of supportive techniques in the evaluation of esophageal disorders and how best to evaluate belching, bloating, distention, and other common GI symptoms.
3. Review updates in the medical management of IBD and the management of dysplasia.
4. Outline the newest screening and surveillance approaches for colorectal and pancreatic cancer.
5. Describe the evaluation process for both living liver donors and recipients, encompassing medical, surgical, and patient perspectives, to ensure optimal outcomes and minimize risks associated with living donor liver transplants.
6. Recognize the pathophysiology and clinical implications of acute kidney injury in cirrhosis, including its impact on patient prognosis and management strategies, to improve early detection and treatment approaches in clinical practice.
7. Review the latest advancements in treatments for hepatocellular carcinoma (HCC), including surgical, locoregional, and systemic therapies.
8. Describe methods to optimize the care of the ambulatory patient with cirrhosis and prevent decompensation.
9. Discover insights into recent advances in managing metabolic dysfunction associated with steatohepatitis (MASH), including pharmacological and lifestyle interventions, to address the growing burden of MASH-related liver disease and improve patient outcomes.
10. Examine the latest developments in hepatitis B treatment, including antiviral therapies.

The Keck School of Medicine of the University of Southern California designates this activity for a maximum of 9.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Cancellation Policy

Cancellations must be received by the USC Office of CME by fax or email by September 9. 20234 by 12:00 pm PDT for a refund. A $50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.


Accessibility Statement
 
Keck School of Medicine Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the USC Office of CME at [email protected].

To book a room at the Westin Pasadena, please scan the QR code below or visit: https://www.marriott.com/en-us/hotels/laxpw-the-westin-pasadena/rooms/

The Keck School of Medicine Healthcare System School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Keck School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.